Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

1(17%)

Results Posted

0%(0 trials)

Terminated

2(33%)

Phase Distribution

Ph phase_2

17%

Ph phase_3

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

4(80.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(2)

Other(1)

Detailed Status

Terminated2

Completed2

unknown1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (20.0%)

Phase 34 (80.0%)

Trials by Status

terminated233%

unknown117%

completed233%

active_not_recruiting117%

Recent Activity

1 active trials

Showing 5 of 6

active_not_recruiting

Clinical Trials (6)

Showing 6 of 6 trials

NCT06142201

A Real-World Study of JT001 for COVID-19

Active Not Recruiting

NCT05242042Phase 2

JT001 (VV116) for the Early Treatment of COVID-19

Terminated

NCT05582629Phase 3

JT001 (VV116) for the Treatment of COVID-19

Completed

NCT05279235Phase 3

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Terminated

NCT05341609Phase 3

Efficacy and Safety of JT001 (VV116) Compared With Paxlovid

Completed

NCT05101135Phase 3

To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Unknown

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6